The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
Abstract Tyrosine kinase inhibitors (TKIs) have revolutionized Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL) treatment. The combination of blinatumomab and a TKI in the frontline setting has shown the safety and efficacy of the chemotherapy‐free treatment approach in pati...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-09-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70161 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206454984900608 |
|---|---|
| author | Xiaoxia Wu Shenqi Lu Xinhui Zhang Zhen Yang Aining Sun Depei Wu Huifen Zhou Miao Miao |
| author_facet | Xiaoxia Wu Shenqi Lu Xinhui Zhang Zhen Yang Aining Sun Depei Wu Huifen Zhou Miao Miao |
| author_sort | Xiaoxia Wu |
| collection | DOAJ |
| description | Abstract Tyrosine kinase inhibitors (TKIs) have revolutionized Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL) treatment. The combination of blinatumomab and a TKI in the frontline setting has shown the safety and efficacy of the chemotherapy‐free treatment approach in patients with Ph + ALL. This retrospective analysis included 19 patients with Ph + ALL and Ph‐like ALL treated with the combination of blinatumomab and a TKI. Of the 14 newly diagnosed patients, the overall response, complete remission (CR), and molecular response (CMR) rates after one cycle of blinatumomab were 100% (10/10), 90% (9/10), and 57% (8/14), respectively. Of the five relapsed patients, the CR and CMR rates were 50% (2/4) and 40% (2/5). Blinatumomab in combination with TKIs is safe and effective and hence this combination therapy could be a viable therapeutic option in front‐line treatment of patients with Ph + ALL. |
| format | Article |
| id | doaj-art-0adf6bb1a01b4097a34a3a5440db646a |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-0adf6bb1a01b4097a34a3a5440db646a2025-02-07T09:08:08ZengWileyCancer Medicine2045-76342024-09-011317n/an/a10.1002/cam4.70161The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemiaXiaoxia Wu0Shenqi Lu1Xinhui Zhang2Zhen Yang3Aining Sun4Depei Wu5Huifen Zhou6Miao Miao7Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University Suzhou ChinaJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University Suzhou ChinaJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University Suzhou ChinaJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University Suzhou ChinaJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University Suzhou ChinaJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University Suzhou ChinaJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University Suzhou ChinaJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University Suzhou ChinaAbstract Tyrosine kinase inhibitors (TKIs) have revolutionized Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL) treatment. The combination of blinatumomab and a TKI in the frontline setting has shown the safety and efficacy of the chemotherapy‐free treatment approach in patients with Ph + ALL. This retrospective analysis included 19 patients with Ph + ALL and Ph‐like ALL treated with the combination of blinatumomab and a TKI. Of the 14 newly diagnosed patients, the overall response, complete remission (CR), and molecular response (CMR) rates after one cycle of blinatumomab were 100% (10/10), 90% (9/10), and 57% (8/14), respectively. Of the five relapsed patients, the CR and CMR rates were 50% (2/4) and 40% (2/5). Blinatumomab in combination with TKIs is safe and effective and hence this combination therapy could be a viable therapeutic option in front‐line treatment of patients with Ph + ALL.https://doi.org/10.1002/cam4.70161BlinatumomabPhiladelphia chromosome–like acute lymphoblastic leukemiaPhiladelphia chromosome‐positive acute lymphoblastic leukemiatyrosine kinase inhibitor |
| spellingShingle | Xiaoxia Wu Shenqi Lu Xinhui Zhang Zhen Yang Aining Sun Depei Wu Huifen Zhou Miao Miao The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia Cancer Medicine Blinatumomab Philadelphia chromosome–like acute lymphoblastic leukemia Philadelphia chromosome‐positive acute lymphoblastic leukemia tyrosine kinase inhibitor |
| title | The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia |
| title_full | The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia |
| title_fullStr | The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia |
| title_full_unstemmed | The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia |
| title_short | The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia |
| title_sort | combination of a tyrosine kinase inhibitor and blinatumomab in patients with philadelphia chromosome positive acute lymphoblastic leukemia or philadelphia chromosome like acute lymphoblastic leukemia |
| topic | Blinatumomab Philadelphia chromosome–like acute lymphoblastic leukemia Philadelphia chromosome‐positive acute lymphoblastic leukemia tyrosine kinase inhibitor |
| url | https://doi.org/10.1002/cam4.70161 |
| work_keys_str_mv | AT xiaoxiawu thecombinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia AT shenqilu thecombinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia AT xinhuizhang thecombinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia AT zhenyang thecombinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia AT ainingsun thecombinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia AT depeiwu thecombinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia AT huifenzhou thecombinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia AT miaomiao thecombinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia AT xiaoxiawu combinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia AT shenqilu combinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia AT xinhuizhang combinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia AT zhenyang combinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia AT ainingsun combinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia AT depeiwu combinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia AT huifenzhou combinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia AT miaomiao combinationofatyrosinekinaseinhibitorandblinatumomabinpatientswithphiladelphiachromosomepositiveacutelymphoblasticleukemiaorphiladelphiachromosomelikeacutelymphoblasticleukemia |